Bone Cancer Market
Number of pages: 100 | Report Format: PDF | Published date: April 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.21 billion |
|
Revenue Forecast in 2031 |
US$ 1.80 billion |
|
CAGR |
4.47% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Treatment Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global bone cancer market was valued at US$ 1.21 billion in 2022 and is expected to register a revenue CAGR of 4.47% to reach US$ 1.80 billion by 2031.
Bone Cancer Market Fundamentals
Bone cancer refers to a variety of malignancies that occur in the bones. Normal bone tissue can be damaged when cancer cells develop in a bone. Primary bone malignancies are tumors that develop in the bone itself. Many cancers that develop in organs or other regions of the body can spread to the bones and different sections of the body. These tumors are known as secondary or metastatic bone malignancies. Breast, prostate, and lung cancers will most likely metastasize to the bones.
Growing incidence of bone cancer, increasing geriatric population, awareness campaigns, and rise in healthcare expenditure are some of the market trends encouraging the growth of the overall market revenue. This report provides the global osteomyelitis market analysis in terms of revenue, market growth, market dynamics, regional landscape, and overall competitive positioning of the major market players.
[67657]
Bone Cancer Market Dynamics
The incidence of bone cancer is on the rise globally. Additionally, advancements in technology, such as the development of targeted therapies, immunotherapy, and precision medicine, are driving the revenue growth of the bone cancer treatment market. These treatments offer improved outcomes and fewer side effects than traditional chemotherapy and radiation therapy. The aging population significantly drives the bone cancer treatment market revenue. In addition, the geriatric population is more susceptible to bone cancer, and the growing geriatric population is increasing the demand for bone cancer treatment. Moreover, the increasing healthcare expenditure is another factor driving the revenue growth of the bone cancer treatment market. Governments and private organizations are investing heavily in developing new treatments and therapies for bone cancer. Awareness campaigns aimed at educating the public about the symptoms and risk factors of bone cancer also contribute to the revenue growth of the bone cancer treatment market. These campaigns are helping to increase the number of people seeking treatment and diagnosis for bone cancer.
However, a few restraints can obstruct the overall market revenue growth. Lack of sufficient knowledge about bone cancer, including its underlying causes and mechanisms, can make it difficult to develop effective treatments. The cost of bone cancer treatment can be very high, particularly for advanced cases that require surgery, chemotherapy, and radiation therapy. Only a limited number of drugs and therapies are available to treat bone cancer, which can limit the options available to patients and doctors. Many drugs and therapies used to treat bone cancer can have significant side effects, such as nausea, fatigue, and loss of appetite, affecting a patient’s quality of life. In some parts of the world, particularly in low-income countries, patients may not have access to the latest treatments and technologies for bone cancer. Despite advances in understanding the disease, funding for bone cancer research remains relatively limited compared to other types of cancer, which can slow progress toward developing new treatments.
Bone Cancer Market Ecosystem
Global bone cancer has been analyzed from the following perspectives: type, treatment type, distribution channel, and region.
Bone Cancer Market by Type
[86766]
Based on type, the global bone cancer market is segmented into osteosarcoma, chondrosarcoma, Ewing sarcoma, and others.
The osteosarcoma segment registered for the largest revenue share in the global market in 2022. Osteosarcoma is a type of bone cancer that arises from immature bone cells and is the most common primary bone cancer affecting children and young adults. Osteosarcoma has the highest incidence among all primary bone cancers. The high incidence of osteosarcoma drives the demand for bone cancer treatment, making it the largest segment in the market. Osteosarcoma is a highly aggressive cancer that requires aggressive treatment. However, the disease often becomes resistant to treatment, making the development of new treatment options critical. With early diagnosis and proper treatment, the survival rate for osteosarcoma is relatively high compared to other primary bone cancers. This has made the disease a focus of research and development efforts to improve the outcomes of patients with osteosarcoma further. Osteosarcoma predominantly affects children and young adults, and there has been a significant focus on pediatric oncology in recent years. This has led to the development of specialized treatment centers and research institutions focused on developing new treatments and improving outcomes for pediatric bone cancer patients.
Similarly, the chondrosarcoma segment is also expected to show notable revenue growth during the forecast period. Chondrosarcoma is a type of bone cancer that arises from cartilage cells and is the second most common primary bone cancer after osteosarcoma. The high incidence of chondrosarcoma contributes to its significant revenue share in the global bone cancer treatment market. Chondrosarcoma is difficult to treat due to its slow-growing nature, making it resistant to chemotherapy and radiation therapy. Surgery is often the preferred treatment option but is not suitable for all patients. These limited treatment options, and the need for more effective therapies, have led to research and development efforts focused on the development of targeted therapies and immunotherapies. While chondrosarcoma is slow-growing cancer, it has a high mortality rate. This has increased efforts to develop new treatments and improve outcomes for patients with chondrosarcoma. With proper treatment, the survival rate for chondrosarcoma patients is relatively high. This has led to a focus on improving the quality of life for patients living with chondrosarcoma. This overall results in the significant revenue share of chondrosarcoma segment.
Bone Cancer Market by Treatment Type
Based on the route of administration, the global bone cancer market is segmented into targeted therapy, chemotherapy, immunotherapy, and others.
Chemotherapy accounts for the largest share of the global market. Chemotherapy is a standard treatment option for many types of cancer, including bone cancer. It involves using drugs to kill cancer cells and prevent them from dividing and multiplying. Chemotherapy has been a standard treatment option for cancer for decades and is widely accepted as an effective treatment option. It is often used as a first-line treatment for bone cancer, and many patients receive chemotherapy in combination with surgery and radiation therapy. Advancements in chemotherapy have led to the development of targeted chemotherapy drugs designed to kill cancer cells while sparing healthy cells. These targeted drugs have fewer side effects than traditional chemotherapy drugs, making them a preferred treatment option for many patients. Chemotherapy is an effective treatment for many types of bone cancer, including osteosarcoma and Ewing sarcoma. It can shrink tumors before surgery, kill any remaining cancer cells after surgery, or in combination with radiation therapy to improve treatment outcomes. Despite its widespread use, chemotherapy is not a cure for bone cancer, and researchers continue to work on improving its effectiveness and minimizing its side effects. There are ongoing efforts to develop new chemotherapy drugs and improve the delivery of existing drugs to improve treatment outcomes for patients with bone cancer.
Bone Cancer Market by Distribution Channel
Based on the distribution channel, the global bone cancer market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies account for the largest revenue share in the global market. Hospital pharmacies have access to specialized medications that are used in the treatment of bone cancer. These medications may not be available at retail pharmacies or other healthcare settings, and hospital pharmacies are better equipped to handle the storage and handling of these drugs. Hospital pharmacists have specialized knowledge and training in using and managing medications used to treat bone cancer. They can provide guidance on dosing, administration, and potential side effects of these medications to healthcare providers and patients. Bone cancer treatment often requires a multidisciplinary approach, with healthcare providers from different specialties working together to develop a treatment plan. Hospital pharmacies are located within hospitals or medical centers, making it easier for healthcare providers to collaborate and coordinate care. Hospital pharmacies also provide access to supportive care medications, such as pain relievers and anti-nausea drugs, that can help manage cancer treatment’s side effects and improve patients’ quality of life. Reimbursement policies for cancer treatment often favor hospital-based care, which can contribute to the dominance of hospital pharmacies in the bone cancer treatment market.
Bone Cancer Market by Region
Based on the region, the global bone cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominates the global bone cancer treatment market. North America has a relatively higher incidence of bone cancer than other regions. North America has a highly developed healthcare infrastructure with advanced medical technologies, highly skilled healthcare professionals, and well-equipped hospitals. This infrastructure supports the diagnosis and treatment of bone cancer, making it easier for patients to access care and leading to better treatment outcomes. The healthcare systems in North America, particularly the United States, have favorable reimbursement policies for cancer treatment. This has encouraged the development of new treatment options and increased the availability of these treatments to patients with bone cancer. The region is home to many leading pharmaceutical and biotechnology companies, research institutions, and academic centers actively developing new therapies for bone cancer. Governments in North America have implemented various initiatives to improve cancer care and increase public awareness of cancer. For example, the US National Cancer Institute provides funding for cancer research and supports the development of new cancer treatments.
Competitive Landscape of the Global Bone Cancer Market
The prominent players operating in the global bone cancer market are:
Strategic Developments in the Bone Cancer Market
Amgen Inc., Novartis AG, Merck & Co. Inc., and Pfizer Inc. are a few key players in the global bone cancer market.
The osteosarcoma segment dominates the global bone cancer market with the largest revenue share.
Asia Pacific region is expected to account for the highest global bone cancer market revenue growth during the forecast period.
The underlying causes and mechanisms that can further make it difficult to develop effective treatments are one of the major restraining factors to the growth of the global market revenue.
Bone cancer refers to a group of tumors that occur in the bones. Normal bone tissue can be harmed when cancer cells develop in the bone. The kind of bone cancer is determined by the type of cell and tissue in which the disease develops.
*Insights on financial performance are subject to the availability of information in the public domain